• New Validation and Clinical Outcome Data From Several Studies on Nanosphere's Gram-Positive and Gram-Negative Blood Culture Tests to Be Presented at ASM 2013

    MAY 16, 2013

    NORTHBROOK, IL -- 05/16/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced that new validation and outcome data for select Verigene® clinical microbiology tests will be presented at the 113th General Meeting of the American Society for Microbiology (ASM) being held in Denver, CO from May 18 to May 21.

  • Nanosphere Announces Distribution and Collaboration Agreement With Hitachi High-Technologies Corporation

    MAY 13, 2013

    NORTHBROOK, IL -- 05/13/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it has signed a distribution and collaboration agreement with Hitachi High-Technologies Corporation (Hitachi High-Tech). The agreement grants Hitachi High-Tech exclusive rights to market Nanosphere products in Japan. As well, the two companies intend to collaborate on assay and platform development.

  • Nanosphere Announces Record First Quarter Revenues and Strengthens Balance Sheet With $27 Million Debt and Equity Financing

    MAY 8, 2013

    NORTHBROOK, IL -- 05/08/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the first quarter ended March 31, 2013. In addition, the Company announced that it secured $27 million in new capital.

  • Nanosphere Obtains CE Mark for Gram-Negative Blood Culture Test

    MARCH 13, 2013

    NORTHBROOK, IL -- (MARKETWIRE) -- 03/13/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it has obtained the CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices for its Gram-Negative Blood Culture test (BC-GN) on the automated sample-to-result Verigene® System. 

  • Nanosphere to Present at The Cowen and Company 33rd Annual Health Care Conference

    FEBRUARY 21, 2013

    NORTHBROOK, Illinois – February 22, 2013 – Nanosphere, Inc., (NasdaqGM: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced that an overview of the company’s business and commercial strategy will be given by Nanosphere’s President and Chief Executive Officer Michael McGarrity at the Cowen and Company 33rd Annual Health Care Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts.  The Company presentation is on Tuesday, March 5 at 11:20am-11:50am Eastern Time.

  • Nanosphere Announces Record Revenues and Placements, and Key Leadership Changes

    FEBRUARY 13, 2013

    NORTHBROOK, IL, February 13, 2013 – Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the fourth quarter and full year ended December 31, 2012.  In addition, the Company announced the appointment of current Vice President of Sales and Marketing and Chief Commercial Officer Michael K. McGarrity to succeed William P. Moffitt as President, and Chief Executive Officer.  

  • Nanosphere to Release Q4 and Full Year 2012 Results and Hold Investor Call on Wednesday, February 13

    FEBRUARY 5, 2013

    NORTHBROOK, Ill., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Nanosphere, Inc., (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, will report its results for the fourth quarter and full year after the market close on Wednesday, February 13, 2013. The company will also hold a live investor conference call and webcast at 5:00 P.M., Eastern Time.

  • Nanosphere Receives FDA Clearance for C. difficile Test

    DECEMBER 10, 2012

    NORTHBROOK, Ill., December 10, 2012– Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today the U.S. Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its C.difficile test on the automated sample-to-result Verigene® System.

  • Nanosphere Receives FDA Clearance to Market Test for Detection of CYP2C19 Mutations Affecting Drug Metabolism

    NOVEMBER 13, 2012

    NORTHBROOK, Ill., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its CYP2C19 Nucleic Acid Test (CYP2C19 Test) on the automated sample-to-result Verigene® System.

  • Nanosphere Test Accurately Detects a Broad Panel of Bacterial Targets and Resistance Determinants Directly From Blood Culture

    OCTOBER 22, 2012

    Cleveland Clinic Study Demonstrates Speed and Accuracy of Nanosphere's Verigene Gram-Positive Blood Culture Test

    NORTHBROOK, Ill., Oct. 22, 2012 (GLOBE NEWSWIRE) -- Nanosphere's (Nasdaq:NSPH) Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) (IUO), based on the company's proprietary array-based nanoparticle technology, demonstrated overall sensitivity and specificity of 99%, respectively, for the detection of a broad panel of gram-positive bacteria from positive blood cultures, according to a recent study. The BC-GP Test also correctly detected the presence or absence of genes encoding vancomycin resistance in Enterococcus spp. and methicillin resistance in Staphylococcus aureus or S. epidermidis. Researchers concluded that the test, which required less than 5 minutes of user hands-on time, provided accurate organism identification and detection of resistance genes compared to routine laboratory methods.

    • Pages